GE HealthCare Technologies GEHC PDx — D&A

Other segment segments

Similar metrics at other companies

PFEBiopharma — D&A

$348M+5.1%

OPKDiagnostics — D&A

$3.93M-31.1%

OPKPharmaceutical — D&A

$18.26M+2.7%

CAHPharmaceutical and Specialty Solutions — D&A

$70M+59.1%

AMP

AMPHPharmaceutical Products — D&A

$14.35M+5.4%

ATRPharma — D&A

$35.64M+14.4%

Questions, answered.

What is GE HealthCare Technologies's pdx — D&A?

GE HealthCare Technologies (GEHC) reported pdx — D&A of $20M in Q1 2026.

How has GE HealthCare Technologies's pdx — D&A changed year-over-year?

GE HealthCare Technologies's pdx — D&A increased by 66.7% year-over-year, from $12M to $20M.

What is the long-term trend for GE HealthCare Technologies's pdx — D&A?

Over 3 years (2022 to 2025), GE HealthCare Technologies's pdx — D&A has grown at a 13.6% compound annual growth rate (CAGR), from $45M to $66M.

What does pdx — D&A mean?

The non-cash expense allocated to the Pharmaceutical Diagnostics segment for the wear and tear of tangible assets and the write-down of intangible assets over time. This reflects the capital intensity of the segment's manufacturing and R&D infrastructure.